Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
S. Steudte-Schmiedgen,
L. Stieler,
Y. Erim,
E. Morawa,
F. Geiser,
P. Beschoner,
L. Jerg-Bretzke,
N. Hiebel and
K. Weidner,
"Correlates and Predictors of PTSD Symptoms Among Healthcare Workers During the COVID-19 Pandemic: Results of the egePan-VOICE Study",
Frontiers in Psychiatry,
vol. 12,
2021.
| DOI: | 10.3389/fpsyt.2021.686667 |
| Datei: | https://doi.org/10.3389/fpsyt.2021.686667 |
A. Ebigbo,
C. Römmele,
C. Bartenschlager and
et al,
"Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment",
Endoscopy,
vol. 53,
no. 2,
2021.
| DOI: | 10.1055/a-1294-0427 |
M. Baumann,
"COVID-19 and mental health in children and adolescents: a diagnostic panel to map psycho-social consequences in the pandemic context",
Discov Ment Health,
vol. 1,
no. 1,
pp. 2,
2021.
| DOI: | 10.1007/s44192-021-00002-x |
N. Ritschel,
H. Radbruch,
C. Herden,
N. Schneider,
C. Dittmayer and
e. a. Franz,
"COVID-19 and the central and peripheral nervous system",
Pathologe,
vol. 42,
pp. 172—182,
2021.
| DOI: | 10.1007/s00292-021-00923-w |
Q. Ul Ain,
A. Hocke and
S. Hedtrich,
"COVID-19 highlights the model dilemma in biomedical research",
Nat Rev Mater,
pp. 1—3,
2021.
W. Roth and
P. Boor,
"COVID-19 im Spiegel der Pathologie [COVID-19 in the mirror of pathology]",
Pathologe,
vol. 42,
no. 2,
pp. 147-148,
2021.
E. Gaitzsch and
et al,
"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma",
HemaSphere,
vol. 5,
pp. e603,
2021.
| DOI: | 10.1097/HS9.0000000000000603 |
E. Gaitzsch,
V. Passerini,
E. Khatamzas and
et al,
"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma",
Hemasphere,
vol. 5,
no. 7,
2021.
| DOI: | 10.1097/HS9.000000000000060 |
S. Heinemann,
A. Bludau,
H. Kaba and
et al,
"COVID-19 surveillance and testing strategies für patiens in German hospitals – results from a cross-sectional study",
DGHM,
2021.
| Datei: | https://www.egms.de/static/de/journals/dgkh/2021-16/dgkh000402.shtml |
A. Bludau,
M. Anton,
S. Heinemann and
et al,
"COVID-19 vaccination and immunization surveillance for employees in German hospitals – results from a cross-sectional study",
DGHM,
2021.
| Datei: |  https://www.dghm-kongress.de/fileadmin/congress/media/dghm2021/pdf/DGHM_2021_digital_Programme_booklet.pdf |
R. Tanacli,
P. Doeblin,
C. Götze,
V. Zieschang,
A. Faragli,
C. Stehning,
G. Korosoglou,
J. Erley,
J. Weiss,
A. Berger and
D. Stahl,
"COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy",
Front Cardiovasc Med,
vol. 8,
pp. 737257,
2021.
| DOI: | 10.3389/fcvm.2021.737257 |
P. Boor,
T. Wiech,
J. Singh,
E. Vonbrunn,
A. Knöll,
M. Hermann,
M. Büttner-Herold,
C. Daniel and
A. Hartmann,
"COVID-19-Auswirkungen auf die Niere [COVID-19 effects on the kidney]",
Pathologe,
vol. 42,
no. 2,
pp. 183-187,
2021.
C. Seeber,
M. Popp,
J. J. Meerpohl and
et al,
"COVID-19-Pandemie: Präferenzen und Barrieren für die Disseminierung von Evidenzsynthesen",
Anaesthesist,
2021.
| DOI: | 10.1007/s00101-021-01037-z |
K. Polotzek,
A. Karch,
J. Karschau,
M. Wagner,
B. Lünsmann,
M. Menk,
C. Römmele and
J. Schmitt,
"COVID-19-Pandemie: Regionale Steuerung der Patienten",
Dtsch Arztebl International,
vol. 118,
no. 3,
pp. 84—,
2021.
N. Ritschel,
H. Radbruch,
C. Herden,
N. Schneider and
et al,
"COVID-19: Auswirkungen auf das zentrale und periphere Nervensystem",
Pathologe,
vol. 42,
pp. 172-182,
Mä.
2021.
| DOI: | https://doi.org/10.1007/s00292-021-00924-x |
C. Werlein,
F. Länger,
M. P. Kühnel and
D. D. Jonigk,
"COVID-19: Auswirkungen auf Lunge und Herz [COVID-19: effects on the lungs and heart]",
Pathologe,
vol. 42,
no. 2,
pp. 164-171,
2021.
L. Loyal,
J. Braun,
L. Henze,
B. Kruse,
M. Dingeldey and
e. a. Reimer,
"Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination",
Science,
2021.
L. Loyal and
et al,
"Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination",
Science (New York, N.Y.),
2021.
| DOI: | 10.1126/science.abh1823 |
M. Metzendorf,
"Das Cochrane COVID-19 Studienregister – eine studienbasierte, strukturierte Datenbank zur effizienten Identifizierung wissenschaftlicher Evidenz",
GMS Med Bibl Inf,
vol. 21,
no. 1-2,
pp. Doc09,
Sep.
2021.
| DOI: | 10.3205/mbi000498 |
C. Edler,
A. Klein,
A. Schröder,
J. Sperhake and
B. Ondruschka,
"Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®)",
Leg Med (Tokyo),
vol. 51,
pp. 101895,
Jul.
2021.
| DOI: | 10.1016/j.legalmed.2021.101895 |
J. Trimpert and
et al,
"Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters",
Viruses,
vol. 13,
2021.
| DOI: | 10.3390/v13112290 |
M. Schwabenland,
H. Salié,
J. Tanevski,
S. Killmer,
M. Lago,
A. Schlaak,
L. Mayer,
J. Matschke,
K. Püschel,
A. Fitzek,
B. Ondruschka,
H. Mei,
T. Boettler,
C. Neumann-Haefelin,
M. Hofmann,
A. Breithaupt,
N. Genc,
C. Stadelmann,
J. Saez-Rodriguez,
P. Bronsert,
K. Knobeloch,
T. Blank,
R. Thimme,
M. Glatzel,
M. Prinz and
B. Bengsch,
"Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions",
Immunity,
vol. 54,
no. 7,
pp. 1594-1610.e11,
2021.
| DOI: | 10.1016/j.immuni.2021.06.002 |
T. Schwarz and
et al,
"Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany",
Emerging infectious diseases,
vol. 27,
2021.
| DOI: | 10.3201/eid2708.211145 |
N. -. Hoff and
et al,
"Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction",
European Journal of Medical Research,
vol. 26,
pp. 98,
2021.
| DOI: | 10.1186/s40001-021-00557-z |
P. Arora and
et al,
"Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance",
Cellular & Molecular Immunology,
vol. 18,
pp. 2557—2559,
2021.
| DOI: | 10.1038/s41423-021-00772-y |
M. Baumann,
M. Berghäuser,
T. Bolz and
T. Martens,
"Den Fokus neu denken - Skizze eines Pandemiemanagements auf Grundlage der Bedürfnisse und Lern- und Entwicklungserfordernissen von Kindern, Jugendlichen und Familien",
2021.
J. Holz,
"Der Erfolg Vietnams im Kampf gegen das Virus",
Südostasien. Zeitschrift für Politik, Kultur, Dialog,
Feb.
2021.
M. Casagrande,
A. Fitzek,
M. Spitzer,
K. Püschel,
M. Glatzel,
S. Krasemann,
D. Nörz,
M. Lütgehetmann,
S. Pfefferle and
M. Schultheiss,
"Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19",
Br J Ophthalmol,
vol. 105,
no. 8,
pp. 1057-1061,
2021.
M. Döpfner,
C. Habbel and
et al,
"Die psychische Belastung von Kindern und Jugendlichen und ihren Familien während der COVID-19-Pandemie und der Zusammenhang mit emotionalen und Verhaltensauffälligkeiten",
Bundesgesundheitsbl,
vol. 64,
2021.
| DOI: | 10.1007/s00103-021-03455-1 |
M. Döpfner,
C. Habbel,
B. Schulte,
K. Schulze-Husmann,
M. Simons,
F. Heuer,
C. Wegner,
S. Bender,
B. Herpertz-Dahlmann and
D. Stahl,
"Die psychische Belastung von Kindern, Jugendlichen und ihren Familien während der COVID-19-Pandemie und der Zusammenhang mit emotionalen und Verhaltensauffälligkeiten",
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz,
vol. 64,
no. 12,
pp. 1522—1532,
2021.
| DOI: | 10.1007/s00103-021-03455-1 |
A. Schuppert,
K. Polotzek,
J. Schmitt,
R. Busse,
J. Karschau and
C. Karagiannidis,
"Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: A time series study based on national surveillance data",
The Lancet Regional Health - Europe,
vol. 6,
pp. 100151,
2021.
| DOI: | 10.1016/j.lanepe.2021.100151 |
| Datei: | https://doi.org/10.1016/j.lanepe.2021.100151 |
R. J. Neumann,
B. Kollmann,
M. M. Plichta,
K. Lieb,
O. Tüscher and
A. Reif,
"Differential impact of COVID-related lockdown on mental health in Germany",
World Psychiatry,
vol. 20,
no. 1,
pp. 140—141,
2021.
| DOI: | 10.1002/wps.20830 |
K. Vanshylla and
et al,
"Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers",
Cell host & microbe,
2021.
| DOI: | 10.1016/j.chom.2021.12.010 |
S. Schlickeiser,
T. Schwarz,
S. Steiner,
K. Wittke,
O. Meyer,
U. Kalus,
A. Pruß,
F. Kurth,
T. Zoller and
D. Stahl,
"Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses",
Front Immunol,
vol. 11,
pp. 628971,
2021.
| DOI: | 10.3389/fimmu.2020.628971 |
F. Heinrich,
C. Romich,
T. Zimmermann,
I. Kniep,
A. Fitzek,
S. Steurer,
M. Glatzel,
D. Nörz,
T. Günther,
M. Czech-Sioli,
N. Fischer,
A. Grundhoff,
M. Lütgehetmann and
B. Ondruschka,
"Dying of VOC-202012/01 - multimodal investigations in a death case of the SARS-CoV-2 variant",
Int J Legal Med,
pp. 1-10,
2021.
| DOI: | 10.1007/s00414-021-02618-8 |
S. Deinhardt-Emmer,
D. Wittschieber,
J. Sanft,
S. Kleemann,
S. Elschner and
e. a. Haupt,
"Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage",
Elife,
vol. 10,
2021.
L. Gieselmann and
et al,
"Effective high-throughput isolation of fully human antibodies targeting infectious pathogens",
Nature Protocols,
2021.
| DOI: | 10.1038/s41596-021-00554-w |
A. Deckert and
D. Stahl,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-020-04982-z |
| Datei: | https://doi.org/10.1186/s13063-020-04982-z |
A. Deckert and
et al,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-020-04982-z |
A. Deckert and
D. Stahl,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): study protocol for a two-factorial randomized controlled multi-arm trial with cluster sampling",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-021-05619-5 |
| Datei: | https://doi.org/10.1186/s13063-021-05619-5 |
A. Deckert,
M. De Allegri and
et al,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): study protocol for a two-factorial randomized controlled multi-arm trial with cluster sampling",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-021-05619-5 |
P. Beschoner,
M. Jarczok,
M. Kempf,
K. Weimer,
F. Geiser,
N. Hiebel,
Y. Erim,
E. Morawa,
S. Steudte-Schmiedgen and
L. Jerg-Bretzke,
"egePan-VOICE study on the psychosocial burden of the Covid-19 pandemic among medical technical assistants",
Z Psychosom Med Psychother,
2021.
S. Zellmer,
M. Kahn,
A. Ebigbo and
et al,
"Ein Jahr Covid-19: Testung, Verwendung von Schutzausrüstung und Auswirkungen auf die Gastrointestinale Endoskopie in Deutschland",
Z Gastroenterol,
vol. 59,
no. 8,
2021.
| DOI: | 10.1055/s-0041-1734140 |
M. Kahn,
S. Zellmer,
A. Ebigbo and
et al,
"Ein Jahr Covid-19: Testung, Verwendung von Schutzausrüstung und Auswirkungen auf die Gastrointestinale Endoskopie in Deutschland",
Z Gastroenterol,
vol. 59,
no. 12,
2021.
| DOI: | 10.1055/a-1649-8184 |
B. Jensen,
N. Luebke,
T. Feldt,
V. Keitel,
T. Brandenburger,
D. Kindgen-Milles,
M. Lutterbeck,
N. F. Freise,
D. Schoeler,
R. Haas,
A. Dilthey,
A. Walker,
J. Timm and
T. Luedde,
"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
The Lancet regional health. Europe,
vol. 8,
pp. 100164,
2021.
Abstract:
BACKGROUND Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. METHODS After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration. FINDINGS After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment. INTERPRETATION Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
| DOI: | 10.1016/j.lanepe.2021.100164 |
Abstract:
BACKGROUND Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. METHODS After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration. FINDINGS After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment. INTERPRETATION Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
B. Jensen,
N. Luebke,
T. Feldt and
et al,
"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
Lancet Reg Health Eur,
vol. 8,
2021.
| DOI: | 10.1016/j.lanepe.2021.100164 |
L. Ruhl and
et al,
"Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks",
Signal transduction and targeted therapy,
vol. 6,
pp. 418,
2021.
| DOI: | 10.1038/s41392-021-00819-6 |
[German]
S. Stillfried,
P. Boor and
D. PANDEMIcs,
"Entwicklung eines kooperativen Obduktionsnetzwerks aus Pathologie, Neuropathologie und Rechtsmedizin",
Pathologe,
pp. 1-5,
2021.
| DOI: | 10.1007/s00292-021-01004-w |
F. Zack,
S. Nigbur,
J. Manhart,
H. Derani,
D. Boy,
V. Kolbe and
A. Büttner,
"Erste Ergebnisse der Obduktionen der im Zusammenhang mit den SARS-CoV-2-Infektionen Verstorbenen aus der Unimedizin Rostock",
Ärztebl Meckl-Vorpom,
vol. 31,
pp. 125-128,
2021.
A. Revet,
J. Hebebrand,
L. Kehoe,
C. Child,
S. Bender and
P. Klauser,
"ESCAP CovCAP survey of heads of academic departments to assess the perceived initial (April/May 2020) impact of the COVID-19 pandemic on child and adolescent psychiatry services",
European Child & Adolescent Psychiatry,
2021.
| DOI: | 10.1007/s00787-020-01699-x |